To determine if mitoquinone (MitoQ) attenuates cisplatin-induced hearing loss in guinea pigs.
Study Design
Prospective and controlled animal study.
Setting
Academic, tertiary medical center.
Subjects and Methods
Guinea pigs were injected subcutaneously with either 5 mg/kg MitoQ (n = 9) or normal saline (control, n = 9) for 7 days and 1 hour before receiving a single dose of 10 mg/kg cisplatin. Auditory brainstem response thresholds were measured before MitoQ or saline administration and 3 to 4 days after cisplatin administration.
Results
Auditory brainstem response threshold shifts after cisplatin treatment were smaller by 28 to 47 dB in guinea pigs injected with MitoQ compared with those in the control group at all tested frequencies (4, 8, 16, and 24 kHz, P = .0002 to .04). Scanning electron microscopy of cochlear hair cells showed less outer hair cell loss and damage in the MitoQ group.
Conclusion
MitoQ reduced cisplatin-induced hearing loss in guinea pigs. MitoQ appears worthy of further investigation as a means of preventing cisplatin ototoxicity in humans.
DaldalAOdabasiOSerbetciogluB. The protective effect of intratympanic dexamethasone on cisplatin-induced ototoxicity in guinea pigs. Otolaryngol Head Neck Surg. 2007;137:747-752.
3.
WatanabeKHessAMichelOYagiT. Nitric oxide synthase inhibitor reduces the apoptotic change in the cisplatin-treated cochlea of guinea pigs. Anticancer Drugs. 2000;11:731-735.
4.
CampbellKCRybakLPMeechRPHughesL. D-methionine provides excellent protection from cisplatin ototoxicity in the rat. Hear Res. 1996;102:90-98.
5.
WimmerCMeesKStumpfTWelschUReichelOSuckfullM. Round window application of D-methionine, sodium thiosulfate, brain-derived neurotrophic factor, and fibroblast growth factor-2 in cisplatin-induced ototoxicity. Otol Neurotol. 2004;25:33-40.
6.
RybakLPRaviRSomaniSM. Mechanism of protection by diethyldithiocarbamate against cisplatin ototoxicity: antioxidant system. Fundam Appl Toxicol. 1995;26:293-300.
RybakLPHusainKEvensonLMorrisCWhitworthCSomaniSM. Protection by 4-methylthiobenzoic acid against cisplatin-induced ototoxicity: antioxidant system. Pharmacol Toxicol. 1997;81:173-179.
9.
KopkeRDLiuWGabaizadehR. Use of organotypic cultures of Corti’s organ to study the protective effects of antioxidant molecules on cisplatin-induced damage of auditory hair cells. Am J Otol. 1997;18:559-571.
10.
ChoeWTChinosornvatanaNChangKW. Prevention of cisplatin ototoxicity using transtympanic N-acetylcysteine and lactate. Otol Neurotol. 2004;25:910-915.
11.
RybakLPHusainKWhitworthCSomaniSM. Dose dependent protection by lipoic acid against cisplatin-induced ototoxicity in rats: antioxidant defense system. Toxicol Sci. 1999;47:195-202.
12.
PattenDAGermainMKellyMASlackRS. Reactive oxygen species: stuck in the middle of neurodegeneration. J Alzheimers Dis. 2010;20(suppl 2):S357-S367.
13.
MurphyMPSmithRA. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol. 2007;47:629-656.
14.
SmithRAHartleyRCMurphyMP. Mitochondria-targeted small molecule therapeutics and probes. Antioxid Redox Signal. 2011;15:3021-3038.
15.
MurphyMPSmithRA. Drug delivery to mitochondria: the key to mitochondrial medicine. Adv Drug Deliv Rev. 2000;41:235-250.
16.
SmithRAPorteousCMCoulterCVMurphyMP. Selective targeting of an antioxidant to mitochondria. Eur J Biochem. 1999;263:709-716.
17.
SmithRAMurphyMP. Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Ann N Y Acad Sci. 2010;1201:96-103.
18.
MatthewsRTYangLBrowneSBaikMBealMF. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci U S A. 1998;95:8892-8897.
19.
ErnsterLDallnerG. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta. 1995;1271:195-204.
20.
SmithRAJMurphyMP. Mitochondria-targeted antioxidants as therapies. Discov Med. 2011;57:106-114.
MukhopadhyayPHorvathBZsengellerZ. Mitochondrial-targeted antioxidants represent a promising approach for prevention of cisplatin-induced nephropathy. Free Radic Biol Med. 2012;52:497-506.
23.
Le PrellCGHughesLFMillerJM. Free radical scavengers vitamins A, C, and E plus magnesium reduce noise trauma. Free Radic Biol Med. 2007;42:1454-1463.
24.
KalinecGMFernandez-ZapicoMEUrrutiaREsteban-CrucianiNChenSKalinecF. Pivotal role of Harakiri in the induction and prevention of gentamicin-induced hearing loss. Proc Natl Acad Sci U S A. 2005;102:16019-16024.
25.
SchmidtHHStockerRVollbrachtC. Antioxidants in translational medicine. Antioxid Redox Signal. 2015;23:1130-1143.
26.
PowellRDSwetJHKennedyKL. MitoQ modulates oxidative stress and decreases inflammation following hemorrhage. J Trauma Acute Care Surg. 2015;78:573-579.
27.
McManusMJMurphyMPFranklinJL. The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer’s disease. J Neurosci. 2011;31:15703-15715.
28.
SergiBFerraresiATroianiDPaludettiGFetoniAR. Cisplatin ototoxicity in the guinea pig: vestibular and cochlear damage. Hear Res. 2003;182:56-64.
29.
LaurellGJungneliusU. High-dose cisplatin treatment: hearing loss and plasma concentrations. Laryngoscope. 1990;100:724-734.
30.
GuanXGanRZ. Effect of middle ear fluid on sound transmission and auditory brainstem response in guinea pigs. Hear Res. 2011;277:96-106.
31.
BabaMMatsumotoYKashioA. Micellization of cisplatin (NC-6004) reduces its ototoxicity in guinea pigs. J Control Release. 2012;157:112-117.
32.
EkbornALindbergALaurellGWallinIEksborgSEhrssonH. Ototoxicity, nephrotoxicity and pharmacokinetics of cisplatin and its monohydrated complex in the guinea pig. Cancer Chemother Pharmacol. 2003;51:36-42.
33.
TaudyMSykaJPopelarJUlehlovaL. Carboplatin and cisplatin ototoxicity in guinea-pigs. Audiology. 1992;31:293-299.
34.
DrottarMLibermanMCRatanRRRobersonDW. The histone deacetylase inhibitor sodium butyrate protects against cisplatin-induced hearing loss in guinea pigs. Laryngoscope. 2006;116:292-296.
35.
SnowBJRolfeFLLockhartMM. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson’s disease. Mov Disord. 2010;25:1670-1674.
36.
GaneEJWeilertFOrrDW. The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver Int. 2010;30:1019-1026.
37.
MercerJRYuEFiggN. The mitochondria-targeted antioxidant MitoQ decreases features of the metabolic syndrome in ATM+/–/ApoE–/– mice. Free Radic Biol Med. 2012;52:841-849.
38.
FinkBDHerleinJAGuoDF. A mitochondrial-targeted coenzyme Q analog prevents weight gain and ameliorates hepatic dysfunction in high-fat-fed mice. J Pharmacol Exp Ther. 2014;351:699-708.
39.
FouretGTolikaELecomteJ. The mitochondrial-targeted antioxidant, MitoQ, increases liver mitochondrial cardiolipin content in obesogenic diet-fed rats. Biochim Biophys Acta. 2015;1847:1025-1035.
Rodriguez-CuencaSCochemeHMLoganA. Consequences of long-term oral administration of the mitochondria-targeted antioxidant MitoQ to wild-type mice. Free Radic Biol Med. 2010;48:161-172.
42.
ChackoBKReilyCSrivastavaA. Prevention of diabetic nephropathy in Ins2(+/)–(AkitaJ) mice by the mitochondria-targeted therapy MitoQ. Biochem J. 2010;432:9-19.
43.
McLachlanJBeattieEMurphyMP. Combined therapeutic benefit of mitochondria-targeted antioxidant, MitoQ10, and angiotensin receptor blocker, losartan, on cardiovascular function. J Hypertens. 2014;32:555-564.
44.
Ojano-DirainCPAntonelliPJ. Prevention of gentamicin-induced apoptosis with the mitochondria-targeted antioxidant mitoquinone. Laryngoscope. 2012;122:2543-2548.
45.
RaoVAKleinSRBonarSJ. The antioxidant transcription factor Nrf2 negatively regulates autophagy and growth arrest induced by the anticancer redox agent mitoquinone. J Biol Chem. 2010;285:34447-34459.
